ILK and chronic myelogenous leukemia, BCR-ABL1 positive: Studies using models of imatinib-resistant CML have also demonstrated the presence of altered interactions with the bone marrow microenvironment (BMM) involving a fibronectin/β3-integrin/ILK pathway.